CARMIEL, Israel--(BUSINESS WIRE)--Protalix BioTherapeutics, Inc. (Amex: PLX), today announced that the Company anticipates completion, during the second half of 2008, of enrollment in its on-going pivotal phase III clinical trial of prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD) for the treatment of Gaucher disease. Currently, clinical trial sites that are participating in the trial are recruiting patients in Europe, the United States, Israel and other countries.
